Your observations are off the chart of reality in my
Your observations are off the chart of reality in my opinion. We are not a candidate for a buy out.
As for other observations that I heard. I just finished the call. I am disappointed that Mahboob is no longer with us. I knew it was a big step backwards for him to come to little ol’ Cytodyn when he came and I had hoped that he would stay long enough to possibly replace Nader as CEO. My assumption is he was head hunted by another Pharma and the offer was too good to pass up. He has I am sure a big networking group who knows what his accomplishments are. I wish him good luck. We will miss his experience but will get bye without him. Nobody is irreplaceable.
It looks like they have it covered with another company coming in to help finish the BLA and they had Amerex working with Mahboob and his 2-3 people he had come to Cytodyn with him. ( Wonder if they went too?) Either way. Amerex probably benefitted from Mahboob enough to complete the formatting of the BLA. It may be the only needed items left are the completion of the receptor occupancy testing from the two companies they have hired to help that. Maybe Mahboob left because his job was complete on why he was hired?
Either way it looks like the BLA will probably be held to a RO testing completion as the delay or maybe still on schedule for late June or early July like we were told before. Either way we move on.
As for Covid it has two different takes for me. One is... we might get an EUA but it will take the extention of the CD-12 trial to 70 people like we were told it would take to achieve a p value in mortality
to get a updated p value. Did you hear that stat of 17.6% mortality in the 55 people in the extention? That seems to be on the table still for EUA. If not then another trial it will take. That was 3 different trial options thrown out there for another trial. If we had revenue we could do all 3. We sure do need some revenue.
The second most likely scenario for quick revenue and possible EUA is another country will be our first EUA. Time will tell on this. It seems closer every PR.
As for cancer having a BTD pre-meeting in the near future. I am happy to hear that but it doesn’t sound like it will happen soon and if it does. That would be a huge deal. Look forward to hearing about that possibility.
It was nice to hear the updates on LH and Dr. Recknor was a pleasure to hear speak to symptoms and how his personal experience was overcome with help from Leronlimab. His outlook for the LH trial was encouraging also. This will be the biggest treating group in Covid for us so hearing positive things are great.
Nash was still ongoing and not an issue with abundant information. Time will tell.
Over all I would say Nader was a little guarded and rightly so with all the armchair quarterbacking questions he was asked about what if...
We didn’t get any great news but we are not dropping the ball in any area and all is stable and it appears they have many many coals in the fire all over the world in seeking sales. This will happen and I believe soon. The Devastation in many countries shows all the need. Part of the puzzle they all seek is a critical ICU drug that will relieve some pressure on the ICU’s in all countries. That’s us...
9
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Drilling for Treasure in Labrador's Rich Earth Hey, ever felt that gritty thrill in your bones? That's what I imagine SAGA Metals must be feeling right now. When you're out there punching holes into Mother Earth hoping to hit pay dirt, and every single one of those holes hits something juicy—trust me, that's like hitting the jackpot before even knowing the lottery...
Continue Reading
Webull's Tangled Web: An Investment Shocker It seems Webull Corporation (NASDAQ: BULL) hasn't been playing it straight with its investors, and now it's caught up in a web of legal trouble. If you've got skin in the game, especially if you nabbed Webull securities between April 2025 and October 2026, this class action lawsuit isn't just a blip—it's your wake-up call. The...
Continue Reading
Big Moves in Military Planning Alright, folks, here's the skinny on something that's bound to shake up the military sector: Watchtower Labs has kicked the door open after its stealthy beginnings with a hefty $35 million in seed funding. Investors like Shield Capital, Conviction, and Founders Fund are throwing their weight behind this AI-powered venture that's poised to...
Continue Reading
Expanding the Family Focus at CHERY Brand Night When I saw the splash that CHERY Auto made at their Brand Night in Wuhu, Anhui, I had to take a moment. It wasn't just about unveiling the All-New TIGGO7 and the TIGGOX7, but a whole philosophy geared towards families and their ever-shifting needs. Now, they didn't skimp on the fanfare—inviting families from places like...
Continue Reading
Shanghai's Moment as a Global Sustainability Hub Shanghai's not pulling any punches, hosting a heavyweight gathering of global leaders, thinkers, and innovators with their eyes set on the prize: a sustainable future. As the 2026 Sustainability Global Leaders Conference unfolds in the bustling Huangpu district from October 20 to 22, more than 300 top-tier minds will churn...
Continue Reading
Pearson's Q3 Performance: Crunch Time Checking the rearview mirror at Pearson's nine-month journey into 2026, it's quite the sight. Q3 revved up with a 6% growth spurt, aligning neatly with market expectations. Ain't that a relief in today's rocky terrain of education and assessment? Holding a tight rein, they're on course to meet the mid-single digit revenue growth they...
Continue Reading
Investigating Robotic Mower Imports Some news for Husqvarna Group today, where the European Commission dropped a disclosure that’s sure to keep the execs on their toes. Yeah, we’re talking about that anti-dumping investigation, where the EU’s been eyeing imports of robotic mowers from China. Now, this isn’t the final bell—just another step in an ongoing...
Continue Reading
The Evolution of GALY's Cocoa Strategy Alright, let's talk chocolate—a staple that somehow turned into high-tech business news. GALY is stepping up its game big time, pushing its cultured cocoa front into both the U.S. and the UAE. If you ask me, it's a smart move, adding some resilience to the cocoa supply chain that otherwise dances on the whims of Mother Nature. GALY...
Continue Reading
First Horizon Under the High-Beam Out here in the high-stakes world of finance, knowing when to move and when to wait is the name of the game. But what happens when your trusted financial partner might just be nodding off at the wheel? That’s exactly the conundrum boiling in the Sunshine State, with First Horizon Bank at the center of a $24 million storm. Allegations...
Continue Reading
Technological sovereignty isn’t just some highbrow jargon tossed around at seminars. It’s all about who gets to steer the ship in the realm of immersive tech. With EU Tech Chief Henna Virkkunen stepping up to the plate at UnitedXR Europe, a swarm of minds are descending on Brussels from December 7 to 9, with Virkkunen's session slated for December 8. You can bet your...
Continue Reading
Top 5 Most Recently Viewed Articles
Growth of Thailand's K-12 Education Sector Accelerates with AI The K-12 education market in Thailand is on an exciting growth trajectory, expected to expand by USD 15.38 billion during the period from 2025 to 2029. This surge is buoyed by greater awareness of the significance of primary education and the integration of advanced technologies in educational settings. With a...
Continue Reading
Pagaya Technologies Increases Funding Capabilities with Castlelake Pagaya Technologies Ltd., based in Tel Aviv and listed on NASDAQ as PGY, is making a significant move in the finance sector through a new Warrant Agreement with Castlelake, a leading global alternative investment manager. This partnership illustrates Pagaya's commitment to enhancing its financial capacity...
Continue Reading
Anixa Biosciences Highlights Ovarian Cancer CAR-T Therapy Progress In an exciting announcement, Anixa Biosciences, Inc. (NASDAQ: ANIX) has declared that Dr. Pamela D. Garzone, the Chief Development Officer, will present significant findings at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. This meeting is a pivotal event for oncology...
Continue Reading
Magna International's Stock Surge Explained Recently, there has been significant buzz around Magna International as the company reported impressive earnings and growth metrics. The rise in stock price reflects favorable adjustments in earnings as well as a revision in sales outlook that has intrigued investors and analysts alike. Understanding Quarterly Metrics In its...
Continue Reading
The global generator market was poised for significant growth back in 2024, targeting an impressive USD 21.4 billion increase fueled by several key factors. With a projected CAGR exceeding 8.09%, the expansion wasn't just a flicker on the radar; it reflected real shifts in industrial dynamics, construction booms, and an undeniable push for uninterrupted power supply...
Continue Reading